Cullinan wins FDA review for cancer therapy developed with Taiho
Cullinan Therapeutics, Inc. Common Stock · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · Now $16.21
+15% in 7d after detection
Post-detection moves
1h
—
1d
+0.3%
3d
+4.8%
7d
+15%
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS